# Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

> **NCT05399459** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 897 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant 25 MG
- **DRUG:** Rimegepant 75 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05399459
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-09
- **Primary completion:** 2024-01-19
- **Final completion:** 2024-01-19
- **Target enrollment:** 897 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399459, "Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05399459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*